Stonehage Fleming Financial Services Holdings Ltd Invests $1.28 Million in Edwards Lifesciences Corporation $EW

Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, Holdings Channel reports. The firm purchased 14,152 shares of the medical research company’s stock, valued at approximately $1,280,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rehmann Capital Advisory Group lifted its position in Edwards Lifesciences by 2.1% during the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after buying an additional 130 shares in the last quarter. McIlrath & Eck LLC grew its holdings in Edwards Lifesciences by 14.6% in the 4th quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock valued at $90,000 after buying an additional 135 shares in the last quarter. Quadrant Capital Group LLC grew its holdings in Edwards Lifesciences by 0.9% in the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after buying an additional 136 shares in the last quarter. Stephens Inc. AR grew its holdings in Edwards Lifesciences by 5.4% in the 4th quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock valued at $239,000 after buying an additional 144 shares in the last quarter. Finally, Composition Wealth LLC increased its stake in shares of Edwards Lifesciences by 1.6% in the 4th quarter. Composition Wealth LLC now owns 9,331 shares of the medical research company’s stock worth $795,000 after acquiring an additional 147 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Mizuho raised their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Leerink Partners raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Citigroup boosted their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Finally, UBS Group assumed coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price target for the company. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Insider Activity

In related news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 1,857 shares of company stock valued at $170,305. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

NYSE:EW opened at $89.97 on Friday. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The stock’s fifty day moving average is $89.48 and its two-hundred day moving average is $84.99. The company has a market capitalization of $51.81 billion, a P/E ratio of 51.71, a P/E/G ratio of 2.38 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same period in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.